| Autor: |
Rayane Aparecida Nonato Rabelo, Diego Rodney Rodrigues de Assis, Alexandre Almeida Oliveira, César Luís Nascimento Barbosa, Rafaela das Dores Pereira, Ricardo Wagner de Almeida Vitor, Wiliam César Bento Régis, Mauro Martins Teixeira, Heloísa Beraldo, Fabiana Simão Machado |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Medicine in Drug Discovery, Vol 18, Iss , Pp 100157- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2590-0986 |
| DOI: |
10.1016/j.medidd.2023.100157 |
| Popis: |
Toxoplasmosis is a disease requiring therapeutic innovation, and thiosemicarbazones with antimicrobial activity are candidates to control Toxoplasma gondii infection. Here, the anti-T. gondii activities of (E)-2-(1-(4-chlorophenylthio)propan-2-ylidene)-hydrazinecarbothioamides (Ca and Cb) were investigated. T. gondii-infected macrophages (MOs) or glial cells treated with Ca or Cb showed a decrease in the number of intracellular parasites. A deficiency in the chemokine receptor CCR2, but not CCR5, partially reduced anti-T. gondii activity induced by Ca or Cb. In contrast, a deficiency in 5-lipoxygenase (5-LO) activity potentiated anti-T. gondii activities induced by these compounds. In vivo treatment with Ca increased the survival of T. gondii-infected wild-type mice, and this was associated with increased IFN-γ and IL-12 production. A deficiency in CCR5 or CCR2 abolished the protective effect of Ca treatment in vivo, while a deficiency in 5-LO increased Cb anti-T. gondii effects. Collectively, our data suggest that Ca and Cb are potential therapeutic candidates for the treatment of toxoplasmosis. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
